Cg Oncology, Inc. · NASDAQ:CGON

Cg Oncology — New England Section of the American Urological Association Annual Meeting 2026

8 slides from Cg Oncology's conference presentation, Oct 24, 2026

  1. Slide 1: Clinical and Pharmacokinetic/Pharmacodynamic Insights From CORE-008 Cohort A

    Clinical and Pharmacokinetic/ Pharmacodynamic Insights From CORE-008 Cohort A PHASE 2 STUDY OF INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC IN PATIENTS WITH HIGH-RISK BCG-NAÏVE NON-MUSCLE INVASIVE BLADDER CANCER For individual reference only. The information accessed through this QR code is Matthew M

  2. Slide 2: Disclosures

    Disclosures • CG Oncology: Clinical trial investigator, consultant • Urogen: Advisory board • Watershed: Steering committee, stocks • Ferring: Advisory board, research support • Pfizer: Advisory board • MGB MIT: Research funding 2

  3. Slide 3: Treatment & Assessment Schedule

    Treatment & Assessment Schedule Optional Ext. Maintenance/ Induction Maintenance/Follow-Up Reinduction Long-Term Follow-up Month 0 3 6 9 12 15 18 21 24/30/36 Instillation (Arms 1, 2) X6 for Non- Clinically Responders Indicated Biopsy • Re-induction allowed for patients with HG Ta and/or CIS at Month

  4. Slide 4: Patient Demographics & Baseline Characteristics

    Patient Demographics & Baseline Characteristics Patients in Safety Dataset N=54 % • Majority of patients are: Sex, Male, n, % 49 90.7 Median Age, Years (Range) 73.5 (69-79) • Male (90.7%) Age, Years, Categories n, % • White (92.6%) < 65 6 11.1 ≥ 65 and < 75 22 40.7 • > 65 years (88.8%) ≥75 26 48.1 •

  5. Slide 5: Arms 1 & 2: Initial Response Rates

    Arms 1 & 2: Initial Response Rates 100 83.7% CR Rate % (n/N) Confidence Interval (95% CI) (95% CI, 70.3- 92.7) Original 79.2% Overall CR Rate At Any Time (%) (57.8, 92.9) Admin** 19 / 24 patients 75 Optimized 88.0% (68.8, 97.5) Admin*** 22 /25 patients 50 CR CR • Median follow-up: 4.6 months (n=41)

  6. Slide 6: Urinary Pharmacokinetic and Pharmacodynamic Insights

    Urinary Pharmacokinetic and Pharmacodynamic Insights • No detectable creto and Geometric Mean (copies/mL) Cretostimogene Replication in Urine low baseline endogenous GM-CSF • Characteristic peak and trough creto levels during induction and maintenance • GM-CSF levels increased GM-CSF Transgene Expre

  7. Slide 7: Arms 1 & 2: Summary and Conclusions

    Arms 1 & 2: Summary and Conclusions • Cretostimogene monotherapy demonstrates efficacy, safety, and tolerability in HR BCG-Naïve NMIBC with CIS • Optimized schedule appears favorable • Pharmacokinetic/pharmacodynamic and clinical insights reinforce cretostimogene’s mechanism of action, treatment sch

  8. Slide 8: Thank You

    Bladder Cancer THANK YOU Patients and Their Families KEY COLLABORATORS CG ONCOLOGY Key Investigators Colin P. N. Dinney, Rochester, NY Ying Chen Study Coordinators Shane M. Pearce, Spokane, WA Pat Keegan Laurence H. Belkoff, Bala Cynwyd, PA Sarah Donatelli Nurses Brian C. Mazzarella, Austin, TX Sara

CG Oncology — New England Section of the American Urological Association Annual Meeting 2026 on 6ix